Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A RETROSPECTIVE ANALYSIS OF THE COST-EFFECTIVENESS OF TREATMENT WITH METASTRON IN PATIENTS WITH PROSTATE-CANCER METASTATIC TO BONE
Autore:
MCEWAN AJB; AMYOTTE GA; MCGOWAN DG; MACGILLIVRAY JA; PORTER AT;
Indirizzi:
CROSS CANC INST,11560 UNIV AVE EDMONTON AB T6G 1Z2 CANADA WAYNE STATE UNIV DETROIT MI 00000
Titolo Testata:
European urology
, volume: 26, anno: 1994, supplemento:, 1
pagine: 26 - 31
SICI:
0302-2838(1994)26:<26:ARAOTC>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
PAIN PALLIATION; SR-89; TRIAL; MANAGEMENT; CARCINOMA; EFFICACY; ADJUVANT; THERAPY; HEALTH;
Keywords:
COST ANALYSIS; ISOTOPE THERAPY; METASTATIC PROSTATE CANCER; METASTRON; PAIN PALLIATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
A.J.B. Mcewan et al., "A RETROSPECTIVE ANALYSIS OF THE COST-EFFECTIVENESS OF TREATMENT WITH METASTRON IN PATIENTS WITH PROSTATE-CANCER METASTATIC TO BONE", European urology, 26, 1994, pp. 26-31

Abstract

A retrospective study was performed on the cost-effectiveness of treatment for advanced prostate cancer metastatic to bone. Patients (n = 29) recruited into the Trans Canada trial at the Cross Cancer Institute, Edmonton and randomized to treatment with Metastron (strontium-89 chloride) (n = 14) or placebo (n = 15) after local field irradiation therapy for pain palliation were studied over their entire survival time. Estimates were made of the direct costs of treatment, i.e. drugs (analgesics and hormonal agents) and external radiotherapy, and the indirect costs (investigations, outpatient visits and inpatient days, eithertotal or for tertiary care) based on records from the referring hospital, the cancer clinic and any hospitals to which the patients may subsequently have been referred. Meaningful differences were apparent between the two groups in direct costs with the group receiving Metastronshowing a reduction over the entire survival time of Can$ 1,720/person compared with placebo; it should be noted that in this analysis neither the costs of the Metastron, nor of the initial radiotherapy, have been included. The Metastron group also showed a reduction in costs ofhospitalization for tertiary care of Can$ 5,696/person, though the total cost of hospitalization was similar in the two groups. These results suggest that treatment with Metastron can bring about reductions inmanagement costs for patients with advanced prostate cancer and, coupled with the findings of the Trans Canada trial on the improvement in quality of life for patients given Metastron, they add financial support to the clinical rationale for the use of Metastron for the palliative treatment of patients with bone metastases resulting from prostate cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:35:10